Evidence to Recommendations Framework: Vaccination with JYNNEOS for Persons At Risk of Mpox

Agam Rao, MD
CAPT, US Public Health Service
Poxvirus and Rabies Branch
Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices

October 25, 2023
Evidence to Recommendations (EtR) Framework

- Structure to describe information considered in moving from evidence to ACIP vaccine recommendations
- Provides transparency around the impact of additional factors on deliberations when considering a recommendation
EtR question

Does ACIP recommend vaccination with the 2-dose* JYNNEOS vaccine series for persons aged 18 years and older at risk† for mpox?

*Dose 2 administered 28 days after dose 1

†Persons at risk:
• Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had one of the following:
  • A new diagnosis of ≥ 1 sexually transmitted disease
  • More than one sex partner
  • Sex at a commercial sex venue
  • Sex in association with a large public event in a geographic area where mpox transmission is occurring
• Sexual partners of persons with the risks described in above
• Persons who anticipate experiencing any of the above
<table>
<thead>
<tr>
<th>Policy question: Should the 2 dose JYNNEOS vaccine series* be recommended for persons aged 18 years and older at risk† for mpox?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong></td>
</tr>
<tr>
<td>Persons aged 18 years and older at risk for mpox</td>
</tr>
<tr>
<td><strong>Intervention</strong></td>
</tr>
<tr>
<td>Vaccination with JYNNEOS®</td>
</tr>
<tr>
<td><strong>Comparison</strong></td>
</tr>
<tr>
<td>No vaccination</td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
</tr>
<tr>
<td>a) Prevention of disease</td>
</tr>
<tr>
<td>b) Severity of disease</td>
</tr>
<tr>
<td>c) Serious adverse events</td>
</tr>
<tr>
<td>d) Myo-/ peri-carditis</td>
</tr>
</tbody>
</table>

*Dose 2 administered 28 days after dose 1
†Persons at risk:
- Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had one of the following:
  - A new diagnosis of ≥ 1 sexually transmitted disease
  - More than one sex partner
  - Sex at a commercial sex venue
  - Sex in association with a large public event in a geographic area where mpox transmission is occurring
- Sexual partners of persons with the risks described in above
- Persons who anticipate experiencing any of the above
## EtR Domains

<table>
<thead>
<tr>
<th>EtR Domain</th>
<th>Question(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Public Health Problem</strong></td>
<td>• Is the problem of public health importance?</td>
</tr>
<tr>
<td><strong>Benefits and Harms</strong></td>
<td>• How substantial are the desirable anticipated effects?</td>
</tr>
<tr>
<td></td>
<td>• How substantial are the undesirable anticipated effects?</td>
</tr>
<tr>
<td></td>
<td>• Do the desirable effects outweigh the undesirable effects?</td>
</tr>
<tr>
<td><strong>Values</strong></td>
<td>• Does the target population feel the desirable effects are large relative to the undesirable effects?</td>
</tr>
<tr>
<td></td>
<td>• Is there important variability in how patients value the outcome?</td>
</tr>
<tr>
<td><strong>Acceptability</strong></td>
<td>• Is the intervention acceptable to key stakeholders?</td>
</tr>
<tr>
<td><strong>Equity</strong></td>
<td>• What would be the impact of the intervention on health equity?</td>
</tr>
<tr>
<td><strong>Feasibility</strong></td>
<td>• Is the intervention feasible to implement?</td>
</tr>
<tr>
<td><strong>Resource Use</strong></td>
<td>• Is the intervention a reasonable and efficient allocation of resources?</td>
</tr>
</tbody>
</table>
Public Health Problem
## Are continued mpox cases of public health importance?

- Yes

- >1.25 million doses of JYNNEOS have been administered in the United States
- However, national vaccine coverage remains lower than ideal, possibly because of lower perceived risk in the last 6 months
- Mpox cases continue to occur domestically and internationally, including in clusters
- Modeling data suggests larger outbreaks may occur if vaccine coverage remains <50% nationally for persons at risk of mpox
- Severe disease and deaths continue to occur
Benefits and Harms
Main source of VE data has been three U.S. studies

- CDC EPIC study
- CDC Multi-jurisdictional study
- New York State study

- Estimated VE for preventing mpox disease has ranged from 66-89% for the 2-dose vaccine series
Multi-jurisdictional study: estimate of VE for preventing infections among immunocompetent vs. self-reported immunocompromised persons

<table>
<thead>
<tr>
<th></th>
<th>Cases</th>
<th>Controls</th>
<th>Adjusted* VE (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Partial vaccination (1 dose)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunocompetent</td>
<td>33</td>
<td>195</td>
<td>77% (52–89)</td>
</tr>
<tr>
<td>Immunocompromised</td>
<td>24</td>
<td>53</td>
<td>71% (8–91)</td>
</tr>
<tr>
<td><strong>Full vaccination (2 doses)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunocompetent</td>
<td>21</td>
<td>161</td>
<td>91% (74–97%)</td>
</tr>
<tr>
<td>Immunocompromised</td>
<td>9</td>
<td>33</td>
<td>82% (23–96%)</td>
</tr>
</tbody>
</table>

*Adjusted for age, race/ethnicity, immunocompromised status, reported close contact with a confirmed/suspected mpox case in 3 weeks prior to index event

- Only recently able to evaluate VE of self-reported immunocompromised, confidence interval is still wide
- Modifications in protocol needed to evaluate VE for objectively confirmed immunocompromised persons
How substantial are desirable anticipated effects of JYNNEOS?

- ACIP previously recommended use of JYNNEOS
  - Persons at increased risk of occupational exposure to orthopoxviruses
  - Persons at-risk for mpox during mpox outbreaks
- Subsequent data has supported its effectiveness for the population impacted by the ongoing outbreak
How substantial are desirable anticipated effects of JYNNEOS?

- ACIP previously recommended use of JYNNEOS
  - Persons at increased risk of occupational exposure to orthopoxviruses
  - Persons at-risk for mpox during mpox outbreaks
- No new safety signals identified from pre-licensure studies
- The adverse events most commonly reported to VAERS have been injection site symptoms (redness, swelling, pain, itching)
Balance between desirable effects relative to undesirable effects of JYNNEOS

Do the desirable effects outweigh the undesirable effects?

- Favors intervention
- Favors comparison
- Favors both
- Favors neither
- Unclear

- Desirable anticipated effects considered large
- Undesirable anticipated effects considered small
EtR Domain: Values
Early in outbreak response: National surveys indicated strong interest in vaccine

- During Aug-Nov 2022, >85% of respondents in the American Transformative HIV Study (AMETHST) were interested in vaccine, and uptake doubled from August to September
- During August-Dec 2022, 50% of Porter-Novelli survey responders who identified as LGBTQ+ felt the vaccination is important to protect from mpox
- During Oct-Nov 2022, >70% of MSM in a San Francisco survey of persons experiencing homelessness reported that they would accept or have accepted vaccination
- During October-December 2022, an American Men’s Interest Survey (AMIS) showed that those who were concerned about mpox were 3.5x more likely to be vaccinated

https://www.cdc.gov/mmwr/volumes/71/ww/mm7135e1.htm
Filardo TD. Vaccine. 2023 Sep 7;41(39):5673-5677.
Early in outbreak: Persons seeking vaccination were, as expected, supportive of the JYNNEOS vaccine

- DC PEP ++ Study: CDC and DC Health collaboration to follow cohort of persons at elevated risk of mpox exposure in Washington D.C. who presented for JYNNEOS vaccination, Aug 2022-Oct 2022
  - Survey with 866 adults
  - >85% agreed or strongly agreed that vaccines for mpox should be available to anyone who wants the vaccine
  - 82% were likely or very likely to get a third dose if it was recommended

- Qualitative interviews August and September 2022 among adults presenting for JYNNEOS vaccine in Washington DC
  - Many participants grateful that LGBTQ+ were given priority vaccine access (suggests interest in vaccine)

Hassan, R. (in press). Sexually Transmitted Diseases
Early in outbreak: Studies indicated conflicting feelings about receiving JYNNEOS vaccines

- Curtis et al. Survey with 320 persons, primarily MSM living in Illinois and at risk for mpox. September 2022
  - 24.1% received 2 vaccine doses, 27.5% received one dose, 47.5% no doses
  - Persons who were vaccinated were more likely to have higher education, know someone with mpox, express concern about their safety, and less likely to report recent food insecurity

- Turpin et al. Qualitative interviews with 24 Black MSM attending HIV prevention-related events in greater D.C. area, May 2022
  - Lack of availability of mpox vaccines was common concern suggesting interest
  - Vaccine hesitancy was also common

More recent: State of vaccine confidence report, June 2023

- Review of mpox-related discussions on 23 news and social media outlets in the Chicago area during the month following the CDPH media release indicating an increase in mpox cases, particularly among previously vaccinated persons

- Findings:
  - Mpox vaccine hesitancy among general public and LGBTQ-affiliated groups noted
  - Questions raised
    - Effectiveness and safety of the vaccine (e.g., sentiment expressed that vaccine is experimental)
    - Distrust in reporting (e.g., Suspicion that mpox reporting is exaggerated)

More recent: Interviews with 18 patients associated with mpox cluster in Chicago, May 2023

- Fully vaccinated, partially vaccinated, unvaccinated interviewed
- Most stated they would recommend vaccine to others
- Most vaccinated persons felt vaccine was effective in reducing severity
- Some assumed it would prevent infection

- Unvaccinated reported initial interest in vaccine when supply was limited and they were unable to receive it; they reported they did not seek it again because case counts decreased so they assumed diminished risk
More recent: Online focus group used by CDC to develop communication material, July 12, 2023

- Session conducted with 52 persons
  - Participant inclusion criteria:
    - Identify as men (including transgender men and transgender women)
    - Unvaccinated for mpox and never diagnosed with mpox
    - 18-45 years of age
    - Sex with 2 or more men within past 6 months
  - Participant demographics: average age 30-34 years; 48% Black, 37% White, 27% Hispanic/Latino; 75% gay, 21% bisexual

- Exposure to communication materials increased interest in receiving mpox vaccine
  - Information about mpox vaccine safety, effectiveness, and current threat of mpox affected interest
  - Current risk of mpox and protecting community were motivating

- Some people did not change their minds
Target population sentiments

Does the target population feel that the desirable effects are large relative to undesirable effects

- No
- Probably no
- Uncertain
- Probably yes
- Yes
- Varies

- Vaccine demand was high early in the outbreak response
- National surveys with the affected population indicate overall interest in JYNNEOS vaccinations
Target population sentiments

Is there important uncertainty about or variability in how much people value the main outcomes

- Important uncertainty or variability
- Possibly important uncertainty or variability
- Probably no important uncertainty or variability
- No important uncertainty or variability
- No known undesirable outcomes

- Interest and intent to get vaccinated varies among the affected population
- Lower perceived risk of mpox may contribute to reduced interest in vaccine later in the outbreak
EtR Domain: Acceptability
Stakeholder perceptions: Health departments

- Health departments requested JYNNEOS and organized vaccination campaigns

New York City opens more monkeypox vaccination appointments today

https://aspr.hhs.gov/SNS/Pages/JYNNEOS-Distribution.aspx
Stakeholder perceptions: Sermo survey of clinicians

- Sermo*: Online community of >1.3 million clinicians
- July 31 - August 1, 2022 survey results of U.S. clinicians (n=415): 69% felt U.S. without enough mpox vaccine to handle outbreak
- September 12, 2022 survey of U.S. clinicians (n=62)
  - 66% had treated at least one mpox patient
  - 76% knew where a patient could get JYNNEOS vaccination
  - 86% wanted to be able to provide vaccination in their office

*Sermo Barometer Reveals Growing Concern Among Global Physicians Regarding Monkeypox

As WHO declares a global health emergency, 65% of doctors say their countries do not have enough vaccines

New York, NY – With the spread of monkeypox on the rise and the World Health Organization (WHO) declaring a global health emergency, findings from a recent survey conducted by Sermo, a physician-first online community and leader in global HCP insights, show there is high concern about public misinformation spreading. The survey also found that while 71% of respondents would recommend vaccination as a preventative measure to a patient who was concerned about contracting monkeypox, 65% of doctors say their country does not have enough vaccines.

The barometer survey included 1,011 physician respondents from 20 countries, with key findings including:

Concerns About Misinformation

Findings from the survey of 1,011 physicians worldwide revealed:

* [https://app.sermo.com/barometer/unitedstates](https://app.sermo.com/barometer/unitedstates)
Porter-Novelli Survey of Pediatricians (n=102) and Family Practice (FP) Practitioners (n=104)

- Added 3 mpox vaccine questions to survey on pediatric COVID-19 vaccine attitudes and behaviors

- Description of respondents' clinical practices:
  - 85% of FP and 88% of Pediatricians cared for children 12-17 years
  - 70% of FP and 60% of Pediatricians cared for patients 18+ years
  - Majority (75%) in private practice; 14% practiced in FQHC
  - 54% had >1500 patients in their practice
Porter Novelli Survey: Preference to provide JYNNEOS within medical practice, PN survey of **Pediatricians** (N=102) and **Family Practitioners** (n=104), August 2023
Shift in vaccine administration sites from public health clinics to medical centers

- Public health providers administered 40% of all vaccines through Mar 2023
- Medical care providers administered an increasing proportion of vaccines since the start of the outbreak
- Pharmacies consistently provided 3-4% of all vaccines
Categories of medical providers administering vaccines

From 2022 to 2023, there were statistically significant increases in vaccines provided by
- Primary care offices
- Federally qualifying health centers (FQHCs)
- Other health centers

FQHC: Federally qualifying health center
Online focus group by CDC: Healthcare provider perceptions of sexual health and mpox

- Conducted to explore provider knowledge, attitudes, and practices related to service delivery, including those specific to mpox
- Recruitment targeting 50 providers via external recruiting firm
- 41 total participants – diverse by gender, race/ethnicity, practice setting, payment methods for patients (e.g., private insurance plans, Medicaid, Medicare, government programs), and clinical profession
- 61% reported spending ≥60% of their time providing sexual health services
- 59% private healthcare setting, 29% private and publicly funded, 10% publicly funded
- 54% in private practice, 20% STD/HIV/family planning clinic, 10% FQHC, 25% in ED or urgent care
Responses from healthcare provider participants (N=41)

- 68% had never managed an mpox case
- 34% believe mpox is a threat to public health
- 32% reported mpox is important to their patient populations
- 51% believe that mpox services (e.g., counseling) should be integrated into standard care for the following reasons
  - Increase access to vaccine
  - Improve education and awareness for patients
  - Ensure STI screening is comprehensive
**Is the intervention acceptable to key stakeholders**

<table>
<thead>
<tr>
<th></th>
<th>No</th>
<th>Probably no</th>
<th>Uncertain</th>
<th>Probably yes</th>
<th>Yes</th>
<th>Varies</th>
</tr>
</thead>
</table>

- Health departments and clinicians are supportive of mpox vaccines even if pediatricians would prefer to refer patients to other clinics to receive JYNNEOS
- Family practitioners would like to be able to provide JYNNEOS in their own clinics
- There has been a shift from JYNNEOS provided by public health providers to JYNNEOS provided by medical center providers, including STI and HIV clinics
EtR Domain: Resource Use
Is the intervention a reasonable and efficient allocation of resources

<table>
<thead>
<tr>
<th>No</th>
<th>Probably no</th>
<th>Uncertain</th>
<th>Probably yes</th>
<th>Yes</th>
<th>Varies</th>
</tr>
</thead>
</table>

- **Current resources**
  - Vaccine only available via national government stockpiles
  - JYNNEOS stockpiled for smallpox preparedness
  - Doses used need to be replenished
  - Significant use of resources (e.g., shipments, transportation, personnel) during the outbreak and routine recommendation could be further drain

- **Potential resources in the future**: Uncertain whether it will be commercialized but if so, unknown costs associated with commercialization
EtR Domain: Equity
Mpox and health equity

- Disproportionate impact of mpox
  - Gay, bisexual, and other MSM
  - Black and Hispanic persons
  - Persons experiencing homelessness

- Any vaccine administered may decrease the disparity between the affected population and others
Impact on health equity

- Will facilitate 1:1 counseling and information sharing in the privacy of a clinic; vaccine recommendation from a clinician is associated with increased vaccine uptake
- $5,000,000 allocated to community-based organizations (CBOs) in September 2023 to advance mpox prevention and vaccination efforts*
  - CBOS essential to increasing vaccination coverage among those at highest risk and provided pivotal role during 2022
  - 42 CBOs funded so far
- If commercialized, there may be an impact on primary sites of vaccination and on health departments
- Recommendation might facilitate broad acceptance of vaccination (e.g., by insurance companies, patients) because endorsed by ACIP after rigorous review

*https://www.cdcfoundation.org/pr/2023/mpox-vaccination-CBO-outreach
What would be the impact on health equity?

Access to vaccine (vs. no vaccine) may improve the health of persons who are at risk for mpox

Routine recommendation may facilitate vaccinations
EtR Domain: Feasibility
Access to JYNNEOS vaccination if ACIP recommends it

- Continue via national stockpiles free of cost to patients and providers
- Mpox provider agreements* do not have a termination date; they will continue as long as vaccine is acquired via the US government program and can include new providers
- Funding† provided to CBOs may improve feasibility
- If commercialized§
  - Via Medicare, Medicaid, commercial plans without copay
  - Uninsured children via Vaccines for Children Program
  - Some uninsured and underinsured adults might have difficulty

*https://www.cdc.gov/poxvirus/mpox/clinicians/provider-agreement.html
†https://www.cdcfoundation.org/pr/2023/mpox-vaccination-CBO-outreach
§Uncertain whether it will be commercialized
Is the intervention feasible to implement?

<table>
<thead>
<tr>
<th></th>
<th>No</th>
<th>Probably no</th>
<th>Uncertain</th>
<th>Probably yes</th>
<th>Yes</th>
<th>Varies</th>
</tr>
</thead>
</table>

- Subcutaneous vaccine; easy to administer
- Standing orders available; JYNNEOS can be stored refrigerated for 8 weeks
- Recent analysis of shift in vaccine providers demonstrates the continued successful integration of JYNNEOS into providers’ practices (e.g., STI and HIV care settings, HIV care pharmacies, LGBTQ+ affirming primary care practices)
- STI, HIV, and most family medicine/internal medicine providers comfortable providing vaccines but some pediatricians may prefer referring patient to other clinics
- If commercialized, similar to other vaccines, cost of vaccine might impact access to some populations
## Summary of EtR

<table>
<thead>
<tr>
<th>Domains</th>
<th>Benefits: How substantial are the desired anticipated effects</th>
<th>Harms: How substantial are undesirable anticipated effects?</th>
<th>Benefit / Harm:</th>
<th>Impact on health equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domains</td>
<td>Large</td>
<td>Small</td>
<td>Favors intervention</td>
<td>Possibly increased</td>
</tr>
<tr>
<td>Values: Does the target population feel desirable effects are large</td>
<td>Is there important uncertainty about or variability in values?</td>
<td>Acceptable to stakeholders?</td>
<td>Yes</td>
<td>Feasible to implement?</td>
</tr>
<tr>
<td></td>
<td>Possibly important uncertainty or variability</td>
<td>Reasonable and efficient allocation of resources?</td>
<td></td>
<td>Probable Yes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Balance of consequences:

- Uncertain
Balance of Consequences

- Undesirable consequences clearly outweigh desirable consequences in most settings
- Undesirable consequences probably outweigh desirable consequences in most settings
- Balance between desirable and undesirable consequences is closely balanced or uncertain
- Desired consequences probably outweigh undesirable consequences in most settings
- Desirable consequences clearly outweigh undesirable consequences in most settings
- There is insufficient evidence to determine the balance of consequences
Proposed recommendation

ACIP recommends vaccination* with the 2-dose† JYNNEOS vaccine series for persons aged 18 years and older at risk for mpox§?

*Interim recommendation that ACIP will revisit in 2-3 years
†Dose 2 administered 28 days after dose 1
§Persons at risk:
• Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had one of the following:
  • A new diagnosis of ≥ 1 sexually transmitted disease
  • More than one sex partner
  • Sex at a commercial sex venue
  • Sex in association with a large public event in a geographic area where mpox transmission is occurring
• Sexual partners of persons with the risks described in above
• Persons who anticipate experiencing any of the above
Questions?

For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.